CHEMAS is a biotechnology company focused on the development of anti-cancer drugs. In particular, our research aims to discover and develop innovative medicines for patients with cancer.
We have developed TetraAs (As4O6), a drug which has shown meaningful benefits against several different cancers in clinical trials. TetraAs is an arsenic compound which recently gained approval from the US FDA for the treatment of acute promyelocytic leukemia (APL) and chronic myeloid leukemia (CML). Other arsenic compounds, As2O3 and As4S4, were also approved as anti-cancer drugs by the US FDA in the 1990s and early 2000s respectively.
TetraAs has a very stable molecular structure. During our safety testing phase in the GLP institution we proved that TetraAs had very little toxicity.
In Phase 1 of our testing phase, which was conducted in the Asan Medical Center, we examined the progress of 15 patients with terminal cancer who had undergone unsuccessful surgical operations as well as anti-cancer chemotherapy and radiotherapy treatments.
We found that for 10 out of 15 patients who used TetraAs their cancer did not progress following treatment and the size of their tumor was in fact reduced. Particularly noteworthy was the lack of adverse side-effects for patients who took TetraAs – we found in fact that their quality of life greatly improved as a result of using TetraAs. With the help of respected doctors and organisations in the industry, we are continuing our research into TetraAs’s benefits and therapeutic potential.
We believe in the value of collaboration, particularly if this helps us achieve our goal of developing breakthrough treatment for patients suffering from cancer. We are keen to develop partnerships with professionals and global pharmaceuticals and welcome the opportunity to discuss such collaborations.
In addition, we place a high value on being a responsible business: we will never stop trying to find treatments which could improve the lives of those suffering from cancer. We are passionate about having a positive, healthy impact on patients and societies in general and our goal is to ultimately bring about positive change in the world.